Skip to main content

Table 3 Clinical and demographic characteristics of the matched patients with multidrug resistant Acinetobacter baumannii pneumonia treated with colistin or tigecycline

From: Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumanniiin a critical setting: a matched cohort analysis

Characteristics

Colistin N = 84

Tigecycline N = 84

p-value

Age

63.8 (19.8)

63.5 (17.7)

.92

Male

63 (75)

65 (77.4)

.67

APACHE II score

21.6 (9.4)

22.0 (8.8)

.99

Ventilator-associated pneumonia

58 (69.1)

60 (71.4)

.74

 Early onset VAP

6 (10.3)

4 (6.7)

.38

 Late onset VAP

52 (90.0)

56 (93.3)

 

Length of hospital stay before enrollment

29.5 (33.7)

29.0 (30.1)

.92

Length of ICU stay before enrollment

20.2 (29.6)

18.5 (17.9)

.56

Duration of treatment

14.0 (11.2)

12.9 (9.3)

.51

Cardiovascular disease

15 (17.9)

15 (17.9)

1.00

Diabetes mellitus

24 (28.6)

27 (32.1)

.59

 Insulin use

20 (23.8)

21 (25)

.85

Chronic kidney disease

22 (26.2)

22 (26.2)

1.00

Liver cirrhosis

2 (2.4)

4 (4.8)

.41

Chronic pulmonary disease

8 (9.5)

8 (9.5)

1.00

Malignancy

2 (2.4)

2 (2.4)

1.00

Autoimmune

3 (3.6)

5 (6.0)

.48

Operation history

40 (47.6)

45 (53.6)

.44

Combination therapy

   

 Aminoglycoside

1 (1.2)

2 (2.4)

.56

 Carbapenem

9 (10.7)

9 (10.7)

1.00

 Sulbactam

1 (1.2)

3 (3.6)

.32

Baseline creatine (mg/dL)

1.70 (1.40)

1.81 (1.60)

.50

Propensity score

0.370 (0.130)

0.370 (0.131)

.97

  1. APACHE II, acute physiology and chronic health evaluation II; ICU, intensive care units; VAP, ventilator-associated pneumonia.